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E-mail address: partrinc@umdnj.edu (N.C. PartridgMatrix metalloproteinase-13 (MMP-13) plays a critical role in parathyroid hormone (PTH)-induced
bone resorption. PTH acts via protein kinase A (PKA) to phosphorylate and stimulate the transacti-
vation of Runx2 for MMP-13 promoter activation. We show here that PTH stimulated Runx2 phos-
phorylation in rat osteoblastic cells. Runx2 was phosphorylated on serine 28 and threonine 340 after
8-bromo cyclic adenosine mono phosphate (8-Br-cAMP) treatment. We further demonstrate that in
the presence of 8-Br-cAMP, the wild-type Runx2 construct stimulated MMP-13 promoter activity,
while the Runx2 construct having mutations at three phosphorylation sites (S28, S347 and T340)
was unable to stimulate MMP-13 promoter activity. Thus, we have identiﬁed the Runx2 phosphor-
ylation sites necessary for PKA stimulated MMP-13 promoter activation and this event may be crit-
ical for bone remodeling.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Parathyroid hormone (PTH) is an essential regulator of calcium
homeostasis. The hormone has multiple actions, including indirect
activation of the osteoclast through osteoblastic production of
RANKL [1] resulting in increased bone resorption, as well as many
direct changes in the functions of the osteoblast. Besides the stim-
ulation of the production of RANKL, bone resorbing hormones such
as PTH increase the production of proteases such as matrix
metalloproteinase-13 (MMP-13; collagenase-3) which appear to
be required for bone and cartilage matrix degradation and the later
action of osteoclasts [2–4]. MMP-13 appears to play a critical role
in PTH-induced bone resorption and calcemic responses and endo-
chondral bone formation [5,6].
In the rat osteoblastic cell line, UMR 106-01, PTH induces
MMP-13 gene transcription through a protein kinase A (PKA)-
dependent pathway requiring de novo protein synthesis [7,8].chemical Societies. Published by E
otein kinase A; 8-Br-cAMP, 8-
atrix metalloproteinase-13;
TLC, thin layer chromatogra-
, glyceraldehyde 3-phosphate
e).Investigation of the regulatory region of the MMP-13 gene identi-
ﬁed the PTH-response elements as being the runt domain (RD at
132/126) and the activator protein-1 (AP-1 at 48/42) bind-
ing sites in the MMP-13 promoter. We have demonstrated a
PTH-dependent cooperative interaction between the sites and the
proteins (Runx2/Fos/Jun) binding to them [9]. However, there
was no signiﬁcant change in the abundance of Runx2 protein bind-
ing to the RD site and there was also no change in the levels of
Runx2 mRNA or protein in UMR cells after PTH treatment [8].
Using a Gal4 fusion construct of the activation domain 3 (AD3) of
Runx2, and in vitro reactions with PKA, we have shown that PTH
acts via PKA to phosphorylate and stimulate the transactivation
of Runx2 through a PKA consensus site in AD3 [8].
Runx2 has been found to be an essential transcription factor for
inducing osteoblast differentiation [9–13]. Runx2 regulates expres-
sion of several genes including alkaline phosphatase, types I and II
collagen, RANKL, TGF-b type I receptor, C/EBPdelta, nuclear matrix
associated proteins, and TWIST, a basic helix–loop–helix transcrip-
tion factor [14]. Runx2 seems to be involved in the balance be-
tween bone formation and bone resorption and participates in
several bone and bone related diseases [14–18]. Runx2 activity
can be modulated in several ways, including direct regulation of
its gene expression, post-translational modiﬁcations, and pro-
tein–protein interactions. In this study we investigated how Runx2lsevier B.V. All rights reserved.
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tion is biologically signiﬁcant for MMP-13 promoter activation.
We identiﬁed Runx2 phosphorylation sites in vivo and their
requirement for PKA stimulation of MMP-13 promoter activity in
osteoblastic and non-osteoblastic cells.
2. Materials and methods
2.1. Reagents and cells
Tissue culture media and reagents were obtained from Invitro-
gen. The Runx2, c-myc tag and phospho tyrosine antibodies were
purchased from Santa Cruz Biotechnology, CA. The phospho threo-
nine antibody was obtained from Calbiochem, CA. Other chemicals
were obtained from Sigma, St. Louis. UMR 106-01 cells were main-
tained in culture in Eagle’s minimal essential medium (EMEM)
supplemented with 10% fetal bovine serum (FBS) at 37 C in a
humidiﬁed atmosphere of 5% CO2 and 95% air. COS-7 and
C3H10T1/2 cells were maintained in DMEM medium plus 10% FBS.
2.2. Immunoprecipitation
Cells were lysed in immunoprecipitation buffer containing pro-
tease inhibitors and phenylmethylsulfonyl ﬂuoride (PMSF). Protein
A/G beads were added to the extracts and allowed to pre-absorb
for 1 h, after which primary antibody and protein A/G bead mix-
ture were added. Incubation was continued at 4 C with agitation
for 2 h or overnight. After washing, the beads were suspended in
2 SDS sample buffer, boiled for 5 min and centrifuged. The pro-
teins in the resulting supernatant were separated by SDS–PAGE
and subjected to Western blotting (8, 9).
2.3. Western blot analysis
The proteins were transferred electrophoretically to polyvinyli-
dene diﬂuoride membrane (Bio-Rad). After blocking in Tris-buf-
fered saline containing 5% (w/v) non-fat dry milk, the membrane
was exposed to primary antibody overnight at 4 C. The membrane
was washed and exposed to horseradish peroxidase-conjugated
secondary antibody. The immunoreactive signals were visualized
using an enhanced chemiluminescence detection kit (Amersham
Biosciences).2.4. Metabolic labeling of Runx2 protein
COS-7 cells were transiently transfected with pCMV–c-myc–
Runx2 construct [15] for 24 h. The cells were then incubated with
100 lCi of [32P]phosphate (Phosphorus-32; Amersham BioSci-
ences) in phosphate free DMEM medium containing 0.1% FBS for
2 h, followed by control or 8-Br-cAMP treatment. Whole cell ly-
sates were prepared and immunoprecipitated with antibody to
the c-myc tag. The immunoprecipitated proteins were fractionated
by 12% SDS–PAGE, followed by autoradiography.2.5. Phosphoamino acid analysis
The radioactive band (Runx2) as visualized by autoradiography
was cut out and incubated for 45 min at 95 C in the presence of
6 N HCl. The resulting samples were dried and redissolved in a
solution containing unlabeled phosphorylated serine, threonine,
and tyrosine standards (Sigma Company, St. Louis). Separation of
the amino acids by thin layer chromatography (TLC) electrophore-
sis and staining of the amino acid standards with ninhydrin were
done as described previously [19]. Visualization of Runx2-derived32P-phosphorylated amino acid(s) was accomplished by
autoradiography.
2.6. Identiﬁcation of phosphorylation sites by mass spectrometry
COS-7 cells were transiently transfected with pCMV–c-myc–
Runx2 construct [15] for 24 h. The cells were then treated with
control or 8-Br-cAMP containing media. Whole cell lysates were
prepared and immunoprecipitated with antibody to the c-myc
tag. The immunoprecipitated proteins were fractionated by 12%
SDS–PAGE, followed by silver staining (Amersham Biosciences).
The gel bands corresponding to the Runx2 proteins based on their
sizes were excised and washed with 30% ACN in 50 mM ammo-
nium bicarbonate prior to 7 lg DTT reduction and 35 lg iodoacet-
amide alkylation. Trypsin (0.2 lg) was used for digestion at 37 C
overnight. The resulting peptides were extracted with 30 ll of 1%
triﬂuoracetic acid (TFA) followed by C18 Ziptip (Millpore Corpora-
tion, Billerica, MA) desalting according to manufacturer’s protocol.
The peptides were dried in a Speedvac, and re-suspended in 10 ll
of solvent A (2% acetonitrile (ACN), 0.1% formic acid (FA)) for LC–
MS/MS analysis. In brief, the peptides were ﬁrst separated by Re-
versed Phase Liquid Chromatography (RPLC, capillary PepMap100
column (75 lm  150 mm, 3 lm, 100 Å, C18), Dionex, Sunnyvale,
CA, USA) in a 60 min linear gradient from 10% solvent A to 40% sol-
vent B (95% ACN, 0.1% FA). The RPLC eluent was directly introduced
into a nano-ESI source on an API-US QTOF tandem MS system
(Waters Corporation, Milford, MA). The ESI capillary voltage was
set at 3000 V. The MS spectra (m/z 400–1900) were acquired in
the positive ion mode. Argon was used as the collision gas and
the collision energy was set within a range between 17 and 55 V,
depending on the charge states and the m/z values of the ions ana-
lyzed. MS/MS spectra were acquired in data-dependent mode, in
which the top ﬁve most abundant precursors with two to ﬁve
charges from eachMS survey scan were selected for fragmentation.
Protein identiﬁcation was performed by searching the MS/MS
spectra against mammalian NCBI database using a local MASCOT
search engine (V. 1.9). Oxidized methionine, carbamidomethyl la-
beled-cysteine and serine/threonine phosphorylation were set as
variable modiﬁcations as the search parameters. The MS/MS spec-
tra of phosphopeptides were manually conﬁrmed.
2.7. Site-directed mutagenesis and transient transfections
The mutations in the Runx2 constructs were carried using the
Quick Change site-directed mutagenesis kit (Stratagene, La Jolla,
CA). The serine and threonine amino acids were converted to ala-
nine. The constructs were veriﬁed by sequencing at the UMDNJ-
RWJMS-core DNA automatic sequencing facility. The plasmid
DNAs were transiently transfected into cells using GeneJammer
(Stratagene). Brieﬂy, cells were plated at 2–4  105/well in six-
well plates in 10% FBS-containing medium. The following day,
the cells were transfected with 1 lg DNA and 5 ll GeneJammer
per well in 1 ml of serum-free medium. After 3 h, 1 ml of 10%
FBS-containing medium were added. After 24 h, the cells were
treated with either control or 8-Br-cAMP (103 M)-containing
media for 24 h. CAT activity was measured by reacting 50 ll of
cell lysate in duplicate in a 100 ll reaction volume consisting
of ﬁnal concentrations of 250 lM n-butyryl-coenzyme A and
23 mM [14C]-chloramphenicol (0.125 lCi/assay). The values were
normalized to protein as determined by the Bradford dye binding
(BioRad, Hercules, CA) method. A standard curve using puriﬁed
CAT was performed every experiment to determine the linear
range of the enzyme assay. The Renilla luciferase construct was
co-transfected to normalize the transfection efﬁciency. The Renil-
la luciferase assay was carried out using the Renilla luciferase as-
say kit from Promega [8,9].
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Total RNA was isolated by a kit from Qiagen (Valencia, CA) and
subjected to real-time RT-PCR (15). Reverse transcriptase reaction
was carried out using TaqMan Reverse Transcription reagents
(Roche, Indianapolis, IN). PCR reactions were performed according
to the real-time thermocycler machine manufacturer’s instructions
(DNA Engine Opticon, MJ Research, MA, USA), which allow real-
time quantitative detection of the PCR product by measuring the
increase in SYBR green ﬂuorescence caused by binding of SYBR
green to double-stranded DNA. The SYBR green kit for PCR reac-
tions was purchased from Perkin Elmer Applied Biosystems
(Wellesley, MA). Primers used in this study were designed using
the PrimerExpress software (Perkin–Elmer Applied Biosystems).
For PCR ampliﬁcation, the following sets of mouse speciﬁc MMP-
13 primers were used:
Sense 50 GCC CTG ATG TTT CCC ATC TA 30
Antisense 50 TTT TGG GAT GCT TAG GGT TG 30
3. Results
3.1. PTH stimulates Runx2 phosphorylation in vitro
We have previously demonstrated that PTH stimulates the
transactivation of AD3 in Runx2 through a consensus PKA site
[8]. We also showed that the puriﬁed PKA catalytic subunit could
phosphorylate this portion of Runx2 in vitro but not if the PKA site
at amino acid 347 in AD3 was mutated. In this paper, to identify
PKA-dependent transactivation of Runx2 for MMP-13 promoter
activation, we ﬁrst examined PTH stimulation of Runx2 phosphor-
ylation in vivo. Whole cell lysates were prepared from control or
PTH-treated UMR 106-01 cells and subjected to immunoprecipita-
tion with either IgG or Runx2 antibody, followed by Western blot
analysis using antibodies for phosphorylated serine, threonine,
and tyrosine. As shown in Fig. 1A, PTH stimulated Runx2 phosphor-
ylation within 5 min in UMR 106-01 cells and this occurred mostly
on serine residues with a small amount at threonine and tyrosine
residues. PTH stimulation of Runx2 phosphorylation at serine,
threonine, and tyrosine residues was seen even out to 30 min after
PTH treatment (Fig. 1B).
3.2. Identiﬁcation of Runx2 phosphorylation in vivo
Since osteoblastic cells contain several Runx isoforms (8) and
overexpression of a Runx2 construct may downregulate its ownA B
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Fig. 1. PTH stimulation of Runx2 phosphorylation in vivo. (A) UMR 106-01 cells
were treated with control or PTH (108 M)-containing media for 5 min. (B) UMR
106-01 cells were treated with control or PTH (108 M)-containing media for 5, 15
and 30 min. Whole cell lysates were prepared and immunoprecipitated with either
IgG or Runx2 antibody and immunoblotted with antibodies as indicated followed
by detection by ECL kit (C, control; P, PTH; IP, immunoprecipitation; IB, immuno-
blot; HC, heavy chain; p, phosphorylated).promoter activity (15), in this study we utilized an expression plas-
mid of c-myc-tagged Runx2 (type II) to speciﬁcally identify type II
Runx2 phosphorylation, and transfected this into COS-7 cells since
these cells do not have endogenous Runx2. The cells were then
metabolically labeled with radioactive free orthophosphate, fol-
lowed by 8-Br-cAMP treatment and immunoprecipitation with c-
myc antibody (Fig. 2A). The effect of PTH is mimicked by using
8-Br-cAMP, a cell permeable form of cAMP which will activate pro-
tein kinase A. The immunoprecipitated Runx2 protein was sub-
jected to acid hydrolysis and TLC analysis as described in Section
2. The results indicate that there was Runx2 phosphorylation on
serines in both control and 8-Br-cAMP treated lysates and there
appeared to be more serine phosphorylation after 5 min of 8-Br-
cAMP treatment (Fig. 2B). This is consistent with our previous re-
sult (Fig. 1) that Runx2 was more greatly phosphorylated on serine
residues than threonine and tyrosine residues in response to PTH
treatment.
3.3. Identiﬁcation of Runx2 phosphorylation sites in vivo
To precisely identify Runx2 phosphorylation sites in vivo, COS-7
cells were transiently transfected with c-myc-tagged Runx2 and
treated with control or 8-Br-cAMP-containing media. Whole cell
lysates were immunoprecipitated with either IgG or c-myc tag
antibody. This was followed by SDS–PAGE fractionation and silver
staining. The two bands indicated by arrows (Fig. 3A) were excised
and subjected to matrix-assisted laser desorption/ionization (MAL-
DI) MS analysis. The results identiﬁed the bottom band as Runx2
and that it was phosphorylated on serines and threonines and
identiﬁed that these were serine 28 (Fig. 3B) and threonine 340
after 8-Br-cAMP treatment (Fig. 3C).
3.4. Functional characterization of Runx2 phosphorylation sites for
MMP-13 promoter activation
In order to assess the biological signiﬁcance of the Runx2 phos-
phorylation sites for MMP-13 promoter activation, the amino acids
were mutated in single or double sites by site-directed mutagene-
sis. The wild-type Runx2 and the Runx2 mutated at these
phosphorylation sites were transiently transfected along with the- c-myc-Runx265 -
B
Control 8-Br-cAMP
- pTyr
- pThr
- pSer
_
_
_
Fig. 2. (A) Metabolic labeling of Runx2 protein. The c-myc-tagged Runx2 construct
(pCMV–c-myc–Runx2) was transiently transfected into COS-7 cells. The cells were
then metabolically labeled with free orthophosphate (100 lCi) for 2 h, followed by
8-Br-cAMP (103 M) treatment for 5 min. Whole cell lysates were prepared and
immunoprecipitated with antibody to the c-myc tag, fractionated by 12% SDS–PAGE
and autoradiographed. (B) Phosphoamino acid analysis of Runx2 protein. The
labeled Runx2 protein from the gel was excised and digested with 6 N HCl, followed
by TLC analysis. The cold phosphorylated serine, threonine and tyrosine amino
acids were included as standards. The cold amino acids were visualized with
Ninhydrin spray and UV light. The labeled phosphorylated amino acids were
visualized by autoradiography.
Fig. 3. MALDI/MS analysis of Runx2 phosphorylation sites in vivo. (A) The c-myc-tagged Runx2 construct (pCMV–c-myc–Runx2) was transiently transfected into COS-7 cells.
The cells were then treated with control or 8-Br-cAMP (103 M)-containing media for 5 min. Whole cell lysates were prepared, immunoprecipitated with antibody to the c-
myc tag, fractionated by 12% SDS–PAGE and silver stained. The two protein bands corresponding to 65 kDa and 80 kDa were excised from the gel and subjected to MALDI/MS
analysis. (B) MS/MS spectrum of a doubly-charged ion corresponds to RFSPPSSSLQPGK plus one phosphorylation site (m/z 734.42). The observed y- and b-ion series conﬁrmed
the peptide sequence and localized the phosphorylation site at S28. (C) MS/MS spectrum of a doubly-charged ion corresponds to GTGLPAITDVPRR plus one phosphorylation
site (m/z 716.87). The observed y- and b-ion series tentatively conﬁrmed the peptide sequence and localized the phosphorylation site at T340.
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C3H10T1/2 cells since the latter are of mesenchymal lineage. The
cells were then treated with control or 8-Br-cAMP-containing
media and CAT activity was measured. Both the wild-type Runx2
and Runx2 constructs having mutations of either single or double
phosphorylation sites still stimulated MMP-13 promoter activity
after 8-Br-cAMP treatment (data not shown). We previously dem-
onstrated the requirement of serine amino acid at 347 in the PKA
site of AD3 of the type II Runx2 for MMP-13 promoter activation
(8). Hence, we mutated this site and used the triple mutant for
transfection experiments. Fig. 4A indicates the changes of serine
(28, 347) and threonine (340) amino acids in the wild-type Runx2
construct into alanine amino acids in the mutant-type Runx2. The
wild-type Runx2 and the Runx2 mutated at these phosphorylation
sites were transiently transfected along with the rat MMP-13 pro-
moter construct into either COS-7 cells or C3H10T1/2 cells. The
Runx2 construct having mutations of all three phosphorylation
sites was unable to stimulate MMP-13 promoter activity in either
of the cell lines (Fig. 4B and C). To determine the importance of
Runx2 phosphorylation sites for endogenous MMP-13 gene
expression, the wild-type and the mutated Runx2 constructs were
transiently transfected into C3H10T1/2 cells, followed by 8-
BrcAMP treatment. Real-time RT-PCR analysis shows that the
wild-type Runx2 construct stimulated MMP-13 mRNA expression
in the presence of 8-BrcAMP; while the mutated Runx2 constructwas unable to increase MMP-13 mRNA expression in the presence
of 8-BrcAMP (Fig. 4D), suggesting the importance of Runx2 phos-
phorylation sites for endogenous MMP-13 gene activation in re-
sponse to 8-BrcAMP treatment.
To determine whether the phosphorylation site mutations af-
fect expression of Runx2 protein, the wild-type and triple-mutant
c-myc-tagged Runx2 constructs were transiently transfected into
C3H10T1/2 cells. Whole cell lysates were prepared and subjected
to Western blot analysis using the c-myc and b-actin antibodies.
Expression of c-myc-tagged wild-type Runx2 and c-myc-tagged
mutant-type Runx2 proteins was seen in C3H10T1/2 cells in re-
sponse to transfection with the c-myc-tagged wild-type Runx2
construct and the c-myc-tagged mutant Runx2 construct, respec-
tively (Fig. 5). There was no endogenous expression of c-myc-
tagged Runx2 proteins in either C3H10T1/2 cells or UMR 106-01
cells (Fig. 5).
4. Discussion
Runx proteins are subject to post-translational modiﬁcations
that affect their activity, in particular phosphorylation [20–22]. In
this study we report that PTH stimulated Runx2 phosphorylation
in rat osteoblastic cells and this occurred mostly on serine residues
with a small amount at threonine and tyrosine residues (Fig. 1).
The phosphorylation that occurs at different amino acids within
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Fig. 4. 8-Br-cAMP stimulation of MMP-13 promoter activation. (A) Schematic diagram of 8-Br-cAMP stimulation of phosphorylated residues in Runx2 (type II). The serine (S)
residues at 28 and 347, and threonine (T) residue at 340 in the Runx2 construct were mutated to alanine residues. (B) The wild-type Runx2 or the Runx2 construct with the
three phosphorylation sites mutated were transiently transfected into COS-7 cells along with the rat MMP-13 promoter for 24 h. (C) The wild-type Runx2 or the Runx2
construct with the three phosphorylation sites mutated, at two different concentrations (1 ng and 100 ng), were transiently transfected into C3H10T1/2 cells along with the
rat MMP-13 promoter for 24 h. The cells were then treated with control or 8-Br-cAMP (103 M)-containing media for 24 h. Whole cell lysates were prepared and assayed for
CAT activity (pmoles of chloramphenicol butyrylated per hour per mg protein). Data represent mean ± S.E. of three replicate plates. (D) The wild-type Runx2 or the Runx2
construct with the three phosphorylation sites mutated were transiently transfected into C3H10T1/2 cells for 24 h. The cells were then treated with control or 8-Br-cAMP
(103 M)-containing media for 4 h. Total RNA was isolated and real-time RT-PCR was carried out using the mouse MMP-13 and GAPDH primers. The MMP-13 mRNA
expression was normalized with GAPDH mRNA expression, and the fold stimulation was calculated over control. The experiment was carried out in triplicate. The asterisks
represent P < 0.05 compared with the wild-type Runx2 (W, wild-type; M, mutant).
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ferently. Even though Runx2 protein level has been reported to
be decreased by prolonged cAMP treatment via ubiquitination
and the proteasomal pathway [23], we found that the total amount
of Runx2 protein after PTH treatment in the time period we used
was apparently unchanged (Fig. 1) [8,9].˟-actin
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Fig. 5. The wild-type and the mutant Runx2 protein expression. C3H10T1/2 cells
were transiently transfected with either the c-myc-tagged wild-type Runx2
construct or the c-myc-tagged mutant Runx2 construct for 24 h. As negative
controls, cells (C3H10T1/2 and UMR 106-01) were transiently transfected with
empty vector. Whole cell lysates were prepared and Western blot analysis was
carried out using the antibodies as indicated. b-Actin has been used as loading
control. IB, immunoblot.In the TLC analysis (Fig. 2B) we could not detect phosphorylated
threonine residues but the MALDI/MS study revealed phosphoryla-
tion of Runx2 at threonine residues (Fig. 3C) in addition to serine
residues. This could be due to either less sensitivity of the TLC tech-
nique due to less incorporation of label or lower loading of the acid
hydrolyzed samples. Even though PTH stimulated Runx2 phos-
phorylation at serine, threonine, and tyrosine residues (Fig. 1), 8-
Br-cAMP treatment of COS-7 cells identiﬁed Runx2 phosphoryla-
tion only at serine (28) and threonine (340) residues by MALDI/
MS analysis (Fig. 3B and C), suggesting that there might be activa-
tion of other intermediate signaling pathway(s) by PTH. We were
not able to detect serine phosphorylation at 347 by MALDI/MS
analysis and that could be due to either hindrance effect of two
amino acids closely located with each other (340, 347) or rapid
dephosphorylation at this amino acid, or technical problems, per-
haps related to dephosphorylation. The phosphorylated threonine
(340) and serine (347) residues in the Runx2 protein are located
in the AD3 region and this region has been previously shown to
transactivate Runx2 through its PKA site [8]. Consistent with these
data, Krishnan et al. showed PKA-dependent increases in endoge-
nous Runx2 activity mediated PTH action [23]. It should be noted
that the labeling and immunoprecipitations for MALDI/MS had to
be done in COS-7 cells because of the poor transfection efﬁciency
in UMR 106-01 cells and the need to use tagged Runx2 to immuno-
precipitate sufﬁcient pure protein for MALDI/MS.
During osteoblastic differentiation of human bone marrow stro-
mal cells, there is increased Runx2 activity which could be due to,
1146 N. Selvamurugan et al. / FEBS Letters 583 (2009) 1141–1146at least in part, phosphorylation of key residues in the Runx2 pro-
tein [24]. Runx2 has been shown to be a substrate for the MAPK
pathway and this pathway can be stimulated by a variety of signals
including those initiated by extracellular matrix, osteogenic
growth factors like BMPs and ﬁbroblast growth factor-2, NELL1
and mechanical loading [25–27]. In these studies, an increase in
Runx2 phosphorylation is coincident with enhanced Runx2 tran-
scriptional activity. Runx2 activity has been reported to be nega-
tively regulated by phosphorylation of two serine residues [28].
Dexamethasone was shown to decrease Runx2 phosphorylation
levels on a serine residue, thereby inducing osteogenesis [29]. Re-
cently it has been reported that ERK-MAPK activation stimulates
osteoblast differentiation and skeletal development through a
pathway involving Runx2 [30]. It appears that the putative signal-
ing cascades or effector molecules could regulate Runx2 activity in
opposite ways by phosphorylating it at different amino acids at dif-
ferent positions. There is a conﬂict of results indicating transcrip-
tional activation or repression of Runx2 by its phosphorylation
status [24–30], and our studies provide evidence that Runx2 phos-
phorylation at serine 28, 347 and threonine 340 residues after 8-
Br-cAMP treatment may be correlated with its transcriptional acti-
vation of the MMP-13 gene (Fig. 4B–D). This transcriptional activa-
tion could result from recruitment or sequestration of factors and
cofactors by phosphorylated Runx2 on the MMP-13 promoter.
Thus, we have identiﬁed for the ﬁrst time the Runx2 phosphoryla-
tion sites necessary for PKA stimulated MMP-13 promoter activa-
tion and this event may be critical for bone remodeling.
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